Bridgewater, NJ, United States of America

Mark Drew


 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Mark Drew

Introduction

Mark Drew, an accomplished inventor based in Bridgewater, New Jersey, has made significant strides in the field of pharmacology. With one patented invention to his name, he has contributed to the development of valuable compounds that hold potential for therapeutic applications.

Latest Patents

Mark Drew is the inventor of a notable patent titled "Isomannide derivatives as inhibitors of soluble epoxide hydrolase." This patent describes a series of compounds characterized by their unique formula (I), where R1, R11, R12, and X possess specific meanings highlighted in the claims. These compounds demonstrate considerable pharmacological activity, acting as highly potent and selective inhibitors of soluble epoxide hydrolase. Their applications extend beyond renal failure, targeting conditions such as diabetic nephropathy, type 2 diabetes mellitus, inflammation, and potentially providing benefits in managing pain, dyslipidemia, and atherosclerosis. The patent also encompasses processes for synthesizing these compounds, emphasizing their inclusion as active ingredients in pharmaceutical developments.

Career Highlights

Currently affiliated with Sanofi, a leading global healthcare company, Mark Drew's work plays a vital role in advancing therapeutic solutions in the pharmaceutical industry. His expertise in pharmacology and innovative approach aids in the ongoing development of essential health products.

Collaborations

Throughout his career, Mark has collaborated with talented professionals, including colleagues Katrin Lorenz and Kristin Breitschopf. These partnerships foster a dynamic environment for innovative thinking and problem-solving within their projects.

Conclusion

Mark Drew's contributions to the field of pharmacology, exemplified by his patent on isomannide derivatives, showcase his commitment to developing new therapeutic avenues. Through his work at Sanofi and collaborations with esteemed colleagues, he continues to influence the future of healthcare innovation and pharmaceutical development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…